Study guide

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines

Board Certified Pediatric Pharmacy Specialist BCPPS

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure

1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation

2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles

2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development

3 Chapter 3: Neonatal Critical Care & Prematurity Complications

3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis

4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections

4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections

5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections

5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections

6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus

6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices

7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders

7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities

8 Chapter 8: Pediatric Cardiology & Hemodynamics

8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management

9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support

9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK

10 Chapter 10: Pediatric Neurology & Psychiatric Disorders

10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders

11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders

11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia

12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care

12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care

13 Chapter 13: Pediatric Medication Safety & Error Prevention

13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions

14 Chapter 14: Pediatric Compounding & Formulation Technology

14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities

15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support

15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation

16 Chapter 16: Pediatric Pain Management, Sedation & Delirium

16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies

17 Chapter 17: Biostatistics & Study Design in Pediatric Research

17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values

18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics

18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations

19 Chapter 19: Pediatric Education, Health Literacy & Communication

19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials

20 Chapter 20: Pediatric Immunizations & Public Health Advocacy

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy

21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics

21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines

Key Takeaways Explain This Topic AI

On December 16, 2025 the CDC adopted individual-based decision-making for the hepatitis B birth dose in infants born to HBsAg-negative mothers, with the first dose given no earlier than 2 months of age when the birth dose is deferred; infants of HBsAg-positive or unknown-status mothers still receive hepatitis B vaccine (plus HBIG when indicated) within 12 hours of birth, with post-vaccination serologic testing at 9 to 12 months.

Rotavirus vaccines (oral live RV5 [3 doses: 2, 4, 6 months] and RV1 [2 doses: 2, 4 months]) have an inflexible administration window: dose 1 cannot be initiated at or after 15 weeks 0 days (maximum age 14 weeks 6 days), and the final dose cannot be administered after 8 months 0 days; history of intussusception and SCID are absolute contraindications.

DTaP is a 5-dose routine series (2, 4, 6, 15-18 months, 4-6 years) indicated strictly for children under 7 years of age; encephalopathy within 7 days of a previous pertussis vaccine not attributable to another cause represents an absolute contraindication to future pertussis antigens.

Routine pneumococcal conjugate vaccination utilizes PCV15 or PCV20 in a 4-dose series (2, 4, 6, 12-15 months); if PCV15 was administered for the primary series, high-risk children require supplemental PPSV23 at least 8 weeks later, whereas completing the PCV20 primary series obviates the need for PPSV23.

ACIP voted on September 18, 2025 that children 12 months through 3 years receive standalone varicella vaccine alongside MMR rather than combination MMRV, because MMRV as dose 1 roughly doubles febrile-seizure risk (about 1 excess seizure per 2,300 to 2,600 children, 7 to 10 days post-vaccination); MMRV remains appropriate for dose 2 at 4 to 6 years.

Last updated: September 2026

20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines

Active immunization during infancy and early childhood represents the cornerstone of pediatric preventive medicine and public health. The Advisory Committee on Immunization Practices (ACIP)—working in harmonized collaboration with the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP)—annually updates the recommended childhood immunization schedule. Pediatric clinical pharmacists must master the precise minimum ages, minimum intervals, formulation differences, high-risk indications, and absolute contraindications that define safe vaccine stewardship from birth through age 6.

Master Childhood Immunization Reference Table (Birth through 6 Years)

Vaccine / Antigen Target Pathogen Routine Dosing Ages Minimum Age Formulation Type Critical Clinical Pearls & Contraindications

HepB ; (Engerix-B, Recombivax HB) Hepatitis B virus Birth dose by individual-based decision-making when the mother is HBsAg-negative (see below), then 1–2 mo and 6–18 mo Birth Inactivated recombinant surface antigen (HBsAg) Final dose must NOT be given before age 24 weeks (164 days). Birth dose protocols differ by maternal HBsAg status and infant weight (<2,000 g vs. >=2,000 g).

Rotavirus ; (RV5: RotaTeq;; RV1: Rotarix) Rotavirus gastroenteritis RV5: 2, 4, 6 mo (3 doses); RV1: 2, 4 mo (2 doses) 6 weeks Live attenuated oral liquid Strict cutoff: Dose 1 maximum age 14 weeks 6 days; final dose maximum age 8 months 0 days. Contraindicated in SCID and history of intussusception.

DTaP ; (Infanrix, Daptacel) Diphtheria, Tetanus, Pertussis 2, 4, 6, 15–18 mo, 4–6 yr (5 doses) 6 weeks Inactivated toxoids + acellular pertussis Approved strictly for age <7 years. Contraindicated if encephalopathy occurred within 7 days of previous dose. Dose 4 acceptable at 12 mo if 6 mo since dose 3.

Hib ; (PRP-T: ActHIB, Hiberix;; PRP-OMP: PedvaxHIB) Haemophilus influenzae type b PRP-T: 2, 4, 6, 12–15 mo (4 doses); PRP-OMP: 2, 4, 12–15 mo (3 doses) 6 weeks Polysaccharide-protein conjugate PedvaxHIB eliminates the 6-month dose. If brands are mixed, 4 doses total are required. Routine immunization stops at age 59 months.

PCV15 / PCV20 ; (Vaxneuvance / Prevnar 20) Streptococcus pneumoniae 2, 4, 6, 12–15 mo (4 doses) 6 weeks Pneumococcal conjugate (CRM197 protein) PCV20 covers 5 additional serotypes (8, 10A, 11A, 12F, 15B). If PCV20 series completed, supplemental PPSV23 is NOT recommended for high-risk children.

IPV ; (IPOL) Poliovirus (Types 1, 2, 3) 2, 4, 6–18 mo, 4–6 yr (4 doses) 6 weeks Inactivated enhanced-potency viral vaccine Final dose must be given on or after 4th birthday and >=6 months after prior dose. Oral polio vaccine (OPV) is no longer used in the United States.

Influenza ; (IIV4: Fluzone, Fluarix;; LAIV4: FluMist) Influenza A & B viruses Annually starting at 6 months of age 6 mo (IIV4);; 2 yr (LAIV4) Inactivated split-virion (IIV4) or Live attenuated nasal (LAIV4) Children aged 6 mo through 8 yr receiving influenza vaccine for the first time require 2 doses separated by >=4 weeks . Standard volume is 0.5 mL IM.

MMR ; (M-M-R II, Priorix) Measles, Mumps, Rubella 12–15 mo, 4–6 yr (2 doses) 12 months Live attenuated viral Dose 1 at 12–15 mo preferred as separate MMR and Varicella to minimize febrile seizure risk. Contraindicated in severe immunocompromise and pregnancy.

Varicella ; (Varivax) Varicella zoster virus 12–15 mo, 4–6 yr (2 doses) 12 months Live attenuated viral Minimum interval between doses is 3 months for children <13 years. Must be separated from other live injectable vaccines by >=28 days if not co-administered.

HepA ; (Havrix, Vaqta) Hepatitis A virus 12–23 mo (2 doses separated by 6–18 mo) 12 months Inactivated whole viral Minimum interval between dose 1 and dose 2 is strictly 6 months. Required for all children regardless of travel risk.

Hepatitis B (HepB) Prevention Protocols from Birth

Perinatal transmission of hepatitis B virus results in chronic infection in up to 90% of infected neonates, predisposing them to cirrhosis and hepatocellular carcinoma. Prevention relies on timely immunization and post-exposure prophylaxis initiated within hours of delivery.

Important

December 16, 2025 change — know which half of the algorithm moved. On that date the CDC adopted ACIP's recommendation of individual-based decision-making (termed shared clinical decision-making on the immunization schedule) for the hepatitis B birth dose in infants born to mothers who test NEGATIVE for HBsAg . The parent and clinician weigh vaccine benefits, vaccine risks, and infection risks — for example a household contact with hepatitis B. When the birth dose is deferred, CDC guidance is that the first dose be given no earlier than 2 months of age . Coverage through the Vaccines for Children Program, CHIP, Medicaid, Medicare, and Marketplace plans is unchanged.

Nothing changed for infants born to HBsAg-positive mothers or mothers of unknown status. Those infants still receive the birth dose of vaccine (plus HBIG where indicated) within 12 hours of birth . ACIP separately recommended that all pregnant women be tested for HBsAg , which is what makes the negative-mother pathway safe to individualize. Note that the printed CDC schedule notes lag these votes; date any conflicting source before answering. Neonatal Hepatitis B Immunization Decision Tree:

  • [Infant Delivered]
  • │
  • ┌──────────────────────────┴──────────────────────────┐
  • ▼ ▼
  • [Maternal HBsAg Positive] [Maternal HBsAg Negative]
  • │ │
  • ┌──────────┴──────────┐ ┌──────────┴──────────┐
  • ▼ ▼ ▼ ▼
  • [Infant >= 2,000 g] [Infant < 2,000 g] [Infant >= 2,000 g] [Infant < 2,000 g]
  • HepB Vaccine + • HepB Vaccine + • Individual-based • Individual-based
  • HBIG within HBIG within decision-making: decision-making;
  • 12 hr (separate 12 hr (separate birth dose OR if deferred, no
  • limbs) limbs) defer (no earlier earlier than age
  • than age 2 mo) 2 mo; otherwise
  • If given at birth, delay to hospital
  • counts as Dose 1 discharge/1 mo
  • Birth dose • Birth dose does • If medically
  • counts as NOT count in stable, 3 doses
  • Dose 1 3-dose series starting at 1 mo
  • Complete 3 doses • Complete 3 addtl
  • PVST at 9-12 mo doses starting at 1 mo
  • PVST at 9-12 mo
  • 1. Maternal HBsAg-Positive Protocol (Unchanged — Time-Critical)

Immediate Dual Prophylaxis: Within 12 hours of birth , administer monovalent Hepatitis B vaccine (0.5 mL IM) AND Hepatitis B Immune Globulin (HBIG, 0.5 mL IM) at separate anatomical sites (e.g., opposite anterolateral thighs).

Infants Weighing <2,000 grams: The birth dose does NOT count toward the required 3-dose series due to reduced immunogenicity in premature neonates. These infants must receive a total of 4 doses (birth dose + 3 additional doses administered at chronological ages 1 month, 2 to 3 months, and 6 months).

Infants Weighing >=2,000 grams: The birth dose counts as Dose 1 of the 3-dose series (subsequent doses at 1–2 months and 6 months).

Post-Vaccination Serologic Testing (PVST): Must be performed at 9 to 12 months of age (or 1 to 2 months after completing the series if delayed). Testing includes anti-HBs (protective if >=10 mIU/mL) and HBsAg (detects chronic infection). Testing should never occur before 9 months to avoid detecting passively acquired maternal anti-HBs or transient post-vaccination HBsAg antigenemia.

2. Maternal HBsAg Status Unknown Protocol

Infant >=2,000 grams: Administer monovalent HepB vaccine within 12 hours of birth . Immediately test maternal blood for HBsAg. If the mother tests positive, administer HBIG as soon as possible, but no later than 7 days of age .

Infant <2,000 grams: Because of high vulnerability and suboptimal response, administer both HepB vaccine AND HBIG (0.5 mL) within 12 hours of birth . The birth dose does not count toward the 3-dose series.

3. Absolute Timing Rules for the Final HepB Dose

The final dose (dose 3 or 4) in the Hepatitis B series must satisfy three mandatory criteria:

Minimum chronological age of 24 weeks (164 days) .

Minimum interval of 16 weeks after dose 1.

Minimum interval of 8 weeks after dose 2.

Rotavirus Vaccines: Formulation Distinctions & Inflexible Windows

Rotavirus is the leading cause of severe dehydrating gastroenteritis in infants worldwide. Two live oral rotavirus vaccines are licensed in the United States, each following distinct schedules: Rotavirus Formulation Comparison & Administration Boundaries:

  • ┌─────────────────────────────┬────────────────────────────────────────────────────────┐
  • │ Parameter │ RV5 (RotaTeq) │ RV1 (Rotarix) │
  • ├─────────────────────────────┼───────────────────────────┼────────────────────────────┤
  • │ Antigen Composition │ Pentavalent human-bovine │ Monovalent human live │
  • │ │ reassortant (G1-G4, P1A) │ attenuated (G1P[8]) │
  • │ Routine Schedule │ 3 doses: 2, 4, 6 months │ 2 doses: 2, 4 months │
  • │ Administration Route/Volume │ Oral liquid (2.0 mL tube) │ Oral liquid (1.5 mL app) │
  • │ Latex in Applicator │ Latex-free │ Natural rubber latex tip │
  • │ Minimum Age for Dose 1 │ 6 weeks 0 days │ 6 weeks 0 days │
  • │ MAXIMUM Age for Dose 1 │ 14 weeks 6 days (strict) │ 14 weeks 6 days (strict) │
  • │ MAXIMUM Age for Final Dose │ 8 months 0 days (strict) │ 8 months 0 days (strict) │
  • │ Minimum Dosing Interval │ 4 weeks │ 4 weeks │
  • └─────────────────────────────┴───────────────────────────┴────────────────────────────┘
  • Inflexible ACIP Age Boundaries

Dose 1 Cutoff: The maximum age for administering Dose 1 is 14 weeks 6 days (104 days) . If an infant reaches 15 weeks 0 days without receiving Dose 1, rotavirus vaccine MUST NOT be initiated . Clinical safety data demonstrate an increased attributable risk of intussusception when the initial dose is given to older infants.

Final Dose Cutoff: The maximum age for the final dose (Dose 2 for RV1 or Dose 3 for RV5) is 8 months 0 days . Any remaining doses are omitted once the infant turns 8 months 0 days, regardless of series completion.

Brand Interruption: If any dose in the series is RV5, or if the brand is unknown, a total of 3 doses must be administered.

Absolute Contraindications & Precautions

Absolute Contraindication 1: Severe Combined Immunodeficiency (SCID). Live rotavirus vaccine can cause protracted wild-type-like viral replication and fatal diarrhea in SCID patients.

Absolute Contraindication 2: History of Intussusception. A documented prior episode of intussusception permanently precludes all rotavirus vaccination due to the risk of recurrence (attributable risk of ~1 to 5 excess cases per 100,000 vaccinated infants, peaking within 3 to 7 days post-dose 1).

Precautions: Spina bifida or bladder exstrophy (Rotarix applicator contains natural rubber latex); acute moderate-to-severe gastroenteritis (defer until illness resolves); altered immunocompetence other than SCID.

DTaP: Schedule, Contraindications & Precautionary Algorithms

DTaP (Diphtheria and Tetanus toxoids and acellular Pertussis) is approved strictly for children younger than 7 years of age (6 weeks through 6 years). For children aged 7 years and older, Tdap or Td is utilized.

5-Dose Routine Schedule

Doses 1, 2, 3: Administered at 2, 4, and 6 months of age (minimum age 6 weeks; minimum interval 4 weeks).

Dose 4: Administered at 15 to 18 months of age (minimum interval 6 months after dose 3). Accelerated Rule: Dose 4 can be administered as early as 12 months of age provided at least 6 months have elapsed since dose 3 and the child is unlikely to return at 15–18 months.

Dose 5: Administered at 4 to 6 years of age prior to school entry. Omission Rule: If Dose 4 was administered on or after the child's 4th birthday and at least 6 months after Dose 3, Dose 5 is not required .

Absolute Contraindications vs. Precautions Safety Triaging for Pertussis-Containing Vaccines (DTaP / Tdap):

  • ┌──────────────────────────────────────────────────────────────────────────────────────┐
  • │ ABSOLUTE CONTRAINDICATIONS (Permanently Precludes Future Pertussis Antigens) │
  • ├──────────────────────────────────────────────────────────────────────────────────────┤
  • │ 1. Severe immediate anaphylaxis to a prior vaccine dose or vaccine component. │
  • │ 2. Encephalopathy (e.g., coma, prolonged seizures, altered consciousness) within │
  • │ 7 days of a prior pertussis vaccine not attributable to another cause. │
  • │ ► Action: Substitute DT (Diphtheria-Tetanus) for all remaining doses. │
  • └──────────────────────────────────────────────────────────────────────────────────────┘
  • ┌──────────────────────────────────────────────────────────────────────────────────────┐
  • │ PRECAUTIONS (Require Risk-Benefit Analysis; Pertussis May Be Deferred or Given) │
  • ├──────────────────────────────────────────────────────────────────────────────────────┤
  • │ • Progressive, unstable neurologic disorder (uncontrolled epilepsy, infantile │
  • │ spasms) ► Defer until neurologic status is clarified and stabilized. │
  • │ • Temperature >= 105°F (>= 40.5°C) within 48 hours without identifiable etiology. │
  • │ • Collapse or shock-like state (hypotonic-hyporesponsive episode [HHE]) within 48 hr.│
  • │ • Persistent, inconsolable crying lasting >= 3 hours within 48 hours. │
  • │ • Convulsions with or without fever within 3 days of prior dose. │
  • │ • Guillain-Barré syndrome (GBS) within 6 weeks of prior tetanus toxoid. │
  • └──────────────────────────────────────────────────────────────────────────────────────┘
  • Haemophilus influenzae type b (Hib) & Pneumococcal Conjugate (PCV15 vs. PCV20)
  • Hib Conjugate Vaccines: PRP-T vs. PRP-OMP

Conjugating the polyribosylribitol phosphate (PRP) capsular polysaccharide to a protein carrier transforms Hib from a T-cell-independent to a T-cell-dependent antigen, establishing robust immunological memory in infants under 2 years of age.

PRP-T (Tetanus Toxoid Conjugate: ActHIB, Hiberix, Pentacel): Requires a 4-dose series (primary series at 2, 4, 6 months; booster at 12–15 months).

PRP-OMP (Meningococcal Outer Membrane Protein Complex: PedvaxHIB, Vaxelis): Induces earlier bactericidal antibody titers after dose 1; requires only a 3-dose series (doses at 2 and 4 months; booster at 12–15 months; the 6-month dose is eliminated ).

Interchangeability Rule: If different brands are administered during the primary series, or if the brand is unknown, a total of 3 primary doses (at 2, 4, and 6 months) must be administered before the 12–15 month booster (4 doses total).

Older Unimmunized Children: Hib is not routinely recommended for healthy children aged >=59 months (5 years) . However, unimmunized children of any age with asplenia, sickle cell disease, HIV, complement deficiency, or undergoing chemotherapy/hematopoietic stem cell transplant (HSCT) require 1 or 2 catch-up doses.

Pneumococcal Conjugate Vaccines: PCV15 vs. PCV20

Invasive pneumococcal disease (IPD) causes bacteremia, meningitis, and pneumonia. ACIP guidelines recommend either PCV15 (Vaxneuvance) or PCV20 (Prevnar 20) for all routine childhood immunizations.

Routine Schedule: 4 doses at 2, 4, 6, and 12 to 15 months (minimum age 6 weeks; minimum interval 4 weeks between infant doses, 8 weeks between dose 3 and 4).

Serotype Coverage: PCV15 includes 15 capsular serotypes conjugated to CRM197 carrier protein. PCV20 contains the 15 serotypes in PCV15 plus 5 additional invasive serotypes: 8, 10A, 11A, 12F, and 15B .

High-Risk Guidelines (Asplenia, Sickle Cell, Immunocompromised, Chronic Renal/Cardiac/Pulmonary Disease, CSF Leak, Cochlear Implants):

If PCV20 is used: Children who complete the 4-dose PCV20 series do NOT require supplemental 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23). PCV20 provides broader coverage while conferring superior mucosal immunity and T-cell memory.

If PCV15 is used: High-risk children aged 2 through 18 years who complete the PCV15 series must receive 1 supplemental dose of PPSV23 at least 8 weeks after the final PCV15 dose to cover additional non-PCV15 serotypes.

MMR and Varicella: Live Vaccines & Febrile Seizure Kinetics

Measles, Mumps, and Rubella (MMR) and Varicella (VAR) are live attenuated viral vaccines administered subcutaneously at 12 to 15 months (Dose 1) and 4 to 6 years (Dose 2).

Combination MMRV (ProQuad) vs. Separate Injections

Dose 1 at 12 to 23 Months: Administering combination MMRV as the initial dose results in an approximately two-fold increased risk of febrile seizures compared to administering MMR and Varicella as separate injections at the same visit. The attributable risk is approximately 1 excess febrile seizure per 2,300 to 2,600 children vaccinated , occurring characteristically 7 to 10 days post-vaccination (coinciding with peak measles viral replication and pyrexia).

Current ACIP Recommendation (voted September 18, 2025; adopted by the CDC Acting Director): Children 12 months through 3 years of age are to be immunized against varicella with the standalone varicella vaccine given at the same visit as MMR , and MMRV is no longer recommended below age 4 . This replaced the long-standing 2009-era rule, under which separate injections were merely preferred for dose 1 at 12 to 47 months and MMRV remained an option if the parent expressed a preference. ACIP also removed MMRV below age 4 from the Vaccines for Children Program. For Dose 2 at 4 to 6 years, MMRV remains appropriate because the excess febrile-seizure risk is confined to the younger first-dose age group.

If MMRV Is Used at All: The minimum interval between two MMRV doses is 3 months .

Source-Dating Caution: The printed CDC schedule notes still carried the older "MMRV may be used if parents or caregivers express a preference" wording after the September 2025 vote. Answer from the newer adopted recommendation and check the effective date of any source that conflicts.

Live Vaccine Spacing Rule: If live injectable vaccines (MMR, Varicella, MMRV, Yellow Fever) are not administered on the same calendar day, they must be separated by a minimum of 28 days (4 weeks) . If administered <28 days apart, the second vaccine is considered invalid and must be repeated at least 28 days after the invalid dose.

Practice Pearls & BCPPS Exam Traps

Exam Trap 1: HepB in the <2,000 g Preterm Infant: Do not count the birth dose toward the 3-dose series in preterm neonates weighing <2,000 g unless the mother was documented HBsAg negative and the infant waited until discharge or 1 month of age. If given at birth to a low birth weight infant, 3 additional doses are required starting at 1 month.

Exam Trap 2: Rotavirus Beyond 14 Weeks 6 Days: If a 16-week-old infant presents for their 2-month well-child checkup having never received a rotavirus vaccine, do not administer rotavirus vaccine . The maximum age for Dose 1 is strictly 14 weeks 6 days.

Exam Trap 3: DTaP vs. Tdap Age Cutoff: DTaP is strictly for children <7 years old. If a 7-year-old child presents unimmunized, administer Tdap , never DTaP.

Exam Trap 4: Influenza 2-Dose Rule: Always check past influenza history. A 4-year-old child receiving influenza vaccine for the first time requires 2 doses separated by at least 4 weeks. If they received only 1 dose in their entire life prior to July 1 of the current season, they still require 2 doses this season.